Skip to main content

Substance Withdrawal Syndrome

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

US WorldMeds
US WorldMedsKY - Louisville
1 program
lofexidine administration in subjects seeking buprenorphine dose reductionPHASE_11 trial
Active Trials
NCT02801357Completed10Est. Aug 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
US WorldMedslofexidine administration in subjects seeking buprenorphine dose reduction

Clinical Trials (1)

Total enrollment: 10 patients across 1 trials

NCT02801357US WorldMedslofexidine administration in subjects seeking buprenorphine dose reduction

Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction

Start: Jun 2016Est. completion: Aug 201610 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.